Aridis moves forward with COVID-19 inhaled antibody development

By The Science Advisory Board staff writers

February 23, 2021 -- Anti-infective therapies firm Aridis Pharmaceuticals said that it has augmented its inhaled AR-711 monoclonal antibody to COVID-19 with a second monoclonal antibody designed to neutralize newly emerging COVID-19 mutated variants.

The company expects that the addition of its AR-713 monoclonal antibody will result in a self-administered, inhalable dual-antibody cocktail that will provide broad coverage of all known high-risk COVID-19 strains. A phase II/II/III clinical trial is expected to begin in the second half of 2021.

Preclinical development services are being supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Coronavirus Immunotherapy Consortium (CoVIC) according to Aridis.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?